Vir Biotechnology (VIR) Change in Account Payables (2018 - 2026)

Vir Biotechnology has reported Change in Account Payables for 9 years, with the latest figure at -$4.2 million in Q1 2026.

• Quarterly Change in Account Payables fell 198.66% year-over-year to -$4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 169.66% YoY) and the FY2025 annual result came in at $5.0 million, up 605.77% from the prior year.
• Change in Account Payables slipped to -$4.2 million in Q1 2026 per VIR's latest filing, from $3.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $8.9 million in Q2 2025 and troughed at -$7.5 million in Q3 2023.
• A 5-year average of $77176.5 and a median of -$934000.0 in 2023 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 406.22% in 2025, down 292.52% in 2025.
• Over 5 years, Change in Account Payables stood at $2.8 million in 2022, then slipped by 6.18% to $2.6 million in 2023, then plunged by 173.7% to -$1.9 million in 2024, then jumped by 252.63% to $3.0 million in 2025, then sank by 243.01% to -$4.2 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$4.2 million, $3.0 million, and -$5.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.